Immuno-oncology programs
GPCRs constitute strategic targets mediating immunosuppression. The company exploits its expertise in the field to move forward small molecule and antibody based-assets toward the clinic.
Immuno-oncology
A2aR/A2bR antagonist (M1069)
EP4 receptor antagonist (DT-9081)
Anti-CCR8 antibody
PAR2 antagonist (DT-9045)
Undisclosed GPCR targets